Gilead’s Truvada faces Teva generics assault amid Descovy switching campaign
When its U.S. patent cliff for HIV med Truvada was still on the horizon, Gilead Sciences won approval for follow-up med Descovy and launched an aggressive campaign to switch patients to the new drug. Now, that cliff is here, and Gilead will have to see if all its hard work has paid off. Israeli drugmaker Teva… Read More »
